SG Americas Securities LLC Invests $153,000 in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

SG Americas Securities LLC purchased a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,189 shares of the specialty pharmaceutical company’s stock, valued at approximately $153,000.

Several other institutional investors have also added to or reduced their stakes in KALV. Price T Rowe Associates Inc. MD lifted its holdings in shares of KalVista Pharmaceuticals by 4.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock valued at $263,000 after acquiring an additional 944 shares during the last quarter. ClariVest Asset Management LLC boosted its holdings in shares of KalVista Pharmaceuticals by 2.8% in the 2nd quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock worth $673,000 after purchasing an additional 1,535 shares during the period. Nicholas Investment Partners LP increased its position in shares of KalVista Pharmaceuticals by 0.9% during the 2nd quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock valued at $2,172,000 after purchasing an additional 1,714 shares during the last quarter. nVerses Capital LLC purchased a new stake in KalVista Pharmaceuticals during the 2nd quarter valued at $25,000. Finally, The Manufacturers Life Insurance Company lifted its position in KalVista Pharmaceuticals by 27.3% in the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock worth $182,000 after buying an additional 3,314 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have issued reports on KALV shares. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th. Needham & Company LLC restated a “buy” rating and issued a $32.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV opened at $12.07 on Friday. The firm has a market cap of $509.21 million, a PE ratio of -3.55 and a beta of 0.89. The company has a 50-day moving average of $11.74 and a 200 day moving average of $12.11. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.21 and a 1-year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. Sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.35 EPS for the current fiscal year.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,135 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $12.40, for a total transaction of $26,474.00. Following the completion of the sale, the insider now directly owns 83,745 shares of the company’s stock, valued at approximately $1,038,438. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, insider Paul K. Audhya sold 2,135 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $12.40, for a total transaction of $26,474.00. Following the transaction, the insider now directly owns 83,745 shares in the company, valued at $1,038,438. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher Yea sold 7,102 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $12.01, for a total value of $85,295.02. Following the completion of the sale, the insider now owns 84,467 shares of the company’s stock, valued at approximately $1,014,448.67. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,804 shares of company stock valued at $372,112 over the last quarter. 12.30% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).